Alexander Swarbrick

Summary

Affiliation: Garvan Institute of Medical Research
Country: Australia

Publications

  1. pmc miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
    Alexander Swarbrick
    Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Nat Med 16:1134-40. 2010
  2. pmc Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response
    Alexander Swarbrick
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst NSW 2010, Australia
    Proc Natl Acad Sci U S A 105:5402-7. 2008
  3. doi Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway
    David R Croucher
    Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Cancer Res 73:1969-80. 2013
  4. doi ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype
    Simon Junankar
    1 The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia 2 St Vincent s Clinical School, Faculty of Medicine, UNSW, Kensington, New South Wales 2033, Australia
    Nat Commun 6:6548. 2015
  5. ncbi Cell cycle machinery: links with genesis and treatment of breast cancer
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
    Adv Exp Med Biol 630:189-205. 2008
  6. doi ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells
    David Gallego-Ortega
    Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
    PLoS Biol 13:e1002330. 2015
  7. doi Therapeutic targets in triple negative breast cancer
    Sandra A O'Toole
    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    J Clin Pathol 66:530-42. 2013
  8. doi MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene
    Yu Wei Phua
    The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW, Sydney, Australia
    Breast Cancer Res 17:83. 2015
  9. pmc Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development
    Radhika Nair
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
    PLoS ONE 5:e11947. 2010
  10. pmc ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer
    Maria Kalyuga
    Cancer Research Program and The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
    PLoS Biol 10:e1001461. 2012

Collaborators

Detail Information

Publications19

  1. pmc miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
    Alexander Swarbrick
    Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Nat Med 16:1134-40. 2010
    ..We demonstrate a new mechanism of p53 regulation in cancer and stem cells and uncover a potential therapeutic target for neuroblastoma...
  2. pmc Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response
    Alexander Swarbrick
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst NSW 2010, Australia
    Proc Natl Acad Sci U S A 105:5402-7. 2008
    ..Mice in which Id1 expression was inactivated also exhibited greatly reduced pulmonary metastatic load. These data demonstrate that established tumors remain sensitive to senescence and that Id1 may be a valuable target for therapy...
  3. doi Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway
    David R Croucher
    Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Cancer Res 73:1969-80. 2013
    ..Together, our results define a novel signaling pathway in basal breast cancer involving Lyn and SgK269 that offers clinical opportunities for therapeutic intervention...
  4. doi ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype
    Simon Junankar
    1 The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia 2 St Vincent s Clinical School, Faculty of Medicine, UNSW, Kensington, New South Wales 2033, Australia
    Nat Commun 6:6548. 2015
    ..These studies identify ID4 as a mammary stem cell regulator, deconvolute the heterogeneity of BLBC and link a subset of mammary stem cells to the aetiology of BLBC. ..
  5. ncbi Cell cycle machinery: links with genesis and treatment of breast cancer
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
    Adv Exp Med Biol 630:189-205. 2008
    ..Furthermore, a more detailed understanding of these pathways may identify new targets for therapeutic intervention particularly in endocrine-unresponsive and endocrine-resistant disease...
  6. doi ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells
    David Gallego-Ortega
    Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia
    PLoS Biol 13:e1002330. 2015
    ..As ELF5 has been previously implicated in the development of antiestrogen resistance, this finding implicates ELF5 as a defining factor in the acquisition of the key aspects of the lethal phenotype in luminal A breast cancer. ..
  7. doi Therapeutic targets in triple negative breast cancer
    Sandra A O'Toole
    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    J Clin Pathol 66:530-42. 2013
    ....
  8. doi MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene
    Yu Wei Phua
    The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW, Sydney, Australia
    Breast Cancer Res 17:83. 2015
    ..In recent years an important role for microRNAs (miRNAs) in a myriad of cellular processes in development and in oncogenesis has emerged...
  9. pmc Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development
    Radhika Nair
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
    PLoS ONE 5:e11947. 2010
    ..Together, these data demonstrate that there is no luminal cell-autonomous role for Id1 in mammary epithelial cell fate determination, ductal morphogenesis and terminal differentiation...
  10. pmc ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer
    Maria Kalyuga
    Cancer Research Program and The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
    PLoS Biol 10:e1001461. 2012
    ....
  11. doi Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer
    Sandra A O'Toole
    Cancer Research, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
    Cancer Res 71:4002-14. 2011
    ..Blockade of Hh signaling to peritumoral stromal cells may represent a novel therapeutic approach in some basal-like breast cancers...
  12. pmc Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer
    Simon Junankar
    Garvan Institute of Medical Research and St Vincent s Clinical School, Faculty of Medicine, UNSW Australia, Sydney, Australia
    Cancer Discov 5:35-42. 2015
    ..These data represent the first compelling in vivo evidence that bisphosphonates can target cells in tumors outside the skeleton and that their antitumor activity is likely to be mediated via TAMs...
  13. doi The Hedgehog signalling pathway as a therapeutic target in early breast cancer development
    Sandra A O'Toole
    Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst 2010, NSW, Australia
    Expert Opin Ther Targets 13:1095-103. 2009
    ..This review highlights important recent developments that affect the potential of the Hh pathway as a novel therapeutic target in early breast cancer...
  14. doi The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini
    C Elizabeth Caldon
    Cancer Research Program, Garvan Institute of Medical Research, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
    Cancer Res 68:3026-36. 2008
    ..In summary, Id1 may contribute to early breast cancer by promoting excessive proliferation through cyclin D1...
  15. pmc ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities
    Radhika Nair
    1 Cancer Research Division and Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia 2 St Vincent s Clinical School, Faculty of Medicine, University of New South Wales, New South Wales, Australia
    Mol Ther 22:1407-15. 2014
    ..Here, we discuss the latest findings in this area and the clinical opportunities that they provide. ..
  16. pmc Interleukin-27 signaling promotes immunity against endogenously arising murine tumors
    Karlo D T Natividad
    Immunological Diseases Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    PLoS ONE 8:e57469. 2013
    ..This is the first study to show that IL-27 promotes protective immune responses against endogenous tumors, which is critical as the basis for future development of an IL-27 based therapeutic agent...
  17. doi Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells
    Falko Hochgräfe
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital Clinical School and Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, New South Wales, Australia
    Cancer Res 70:9391-401. 2010
    ....
  18. ncbi Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1
    Alexander Swarbrick
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia
    Oncogene 24:381-9. 2005
    ..These data indicate that in mammary epithelial cells, Id1 has cell cycle regulatory functions that are similar to those of c-Myc, and suggest that cyclin D1 may be involved in Id1 regulation of cell cycle progression...
  19. ncbi p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells
    Jason S Carroll
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia
    Cancer Res 63:4322-6. 2003
    ..These data suggest that agents that up-regulate p27(Kip1) or inhibit growth factor signaling via the extracellular signal-regulated kinases should be tested as therapeutic strategies in tamoxifen-resistant breast cancer...